Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events: Economic Evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective

Author: Peter K. Schädlich  

Publisher: Adis International

ISSN: 1170-7690

Source: PharmacoEconomics, Vol.22, Iss.15, 2004-01, pp. : 955-973

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract